

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1048 daily bars · split adjusted
Current price $3.26
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 16, 25 |
Daily · Wilder smoothing
| Johnson Rice |
| downgrade |
| Buy |
| Hold |
| Jul 17, 25 | Piper Sandler | maintain | Neutral | Neutral |
| May 21, 25 | Johnson Rice | maintain | Accumulate | Buy |
| Nov 18, 24 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 15, 24 | Piper Sandler | maintain | Neutral | Neutral |
| Nov 16, 23 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 14, 23 | Piper Sandler | downgrade | Overweight | Neutral |
| Jul 17, 23 | Jefferies | downgrade | Buy | Hold |
| Jun 13, 23 | Piper Sandler | maintain | Overweight | Overweight |
Classic floor pivots from 2025-12-26
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.99 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 22.58 | Oscillator | Neutral |
| Williams %R (14) | -77.42 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.04 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 13.16 (+DI 21.6 / -DI 24.7) | Trend | Neutral |
| EMA 20 | 3.31 | MA | Sell |
| SMA 20 | 3.34 | MA | Sell |
| EMA 50 | 3.36 | MA | Sell |
| SMA 50 | 3.35 | MA | Sell |
| SMA 200 | 3.12 | MA | Strong Buy |
Stock news · updated daily
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors Research shows registered dietitian-led medical nutrition therapy can improve glucose control and cardiometabolic health outcomes, highlighting the power of combining glucose data plus human expertise1 ABBOTT PARK, Ill. and NEW YORK, Sept.
Proceeds expected to provide non-dilutive funding for core operations at Myakka City and to reduce existing real estate debt MIAMI, FL / ACCESS Newswire / August 21, 2026 / RenX Enterprises Corp. (NASDAQ:RENX) ("RenX" or the "Company") today announced that a joint venture in which its subsidiary holds a 50% interest has entered into a purchase and sale agreement to sell the Norman Berry property, an approximately 7.7 acre parcel in East Point, Fulton County, Georgia, for a purchase price of $2.6 million. The purchaser is a Florida-based real estate development company.
Edmonton, Alberta--(Newsfile Corp. - August 14, 2026) - Bri-Chem Corp. (TSX: BRY) ("Bri-Chem" or "Company"), a leading North American oilfield chemical distribution and blending company, is pleased to announce its 2026 second quarter financial results.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Nov 5, 2025 | 0.07 | -0.08 | Miss -214.3% | $155.8M |
| Aug 6, 2025 | 0.01 | 0.43 | Beat 4225.0% | $210.1M |
| May 8, 2025 | 0.10 | 0.12 | Beat 20.0% | $177.2M |
| Mar 12, 2025 | 0.12 | 0.21 | Beat 75.0% | $193.5M |
| Nov 7, 2024 | 0.15 | 0.14 | Miss -6.7% | $184.3M |
| Aug 9, 2024 | 0.20 | 0.18 | Miss -10.0% | $203.7M |
FY2024 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Dec 18, 25 | Bob Matthew Regis | director | M-Exempt | 22,659 @ $47.21 | $1.07M |
| Dec 18, 25 | Bob Matthew Regis | director | D-Return | 27,911 @ $47.21 | $1.32M |
| Dec 18, 25 | Bob Matthew Regis | director | M-Exempt | 22,659 | — |
| Dec 18, 25 | Hornbaker Renee J | director | M-Exempt | 33,233 @ $47.21 | $1.57M |
| Dec 18, 25 | Hornbaker Renee J | director | D-Return | 122,205 @ $47.21 | $5.77M |
| Dec 18, 25 | Hornbaker Renee J | director | M-Exempt | 33,233 | — |
| Dec 18, 25 | Shourie Rajath | director | M-Exempt | 22,659 @ $47.21 | $1.07M |
| Dec 18, 25 | Shourie Rajath | director | D-Return | 127,337 @ $47.21 | $6.01M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Feb 17, 2026 | 2026-02-17 14:30:19 | View |
| 15-12G/A | Jan 9, 2026 | 2026-01-09 17:30:29 | View |
| 15-12G | Jan 6, 2026 | 2026-01-06 16:55:43 | View |
| EFFECT | Dec 22, 2025 | 2025-12-23 00:15:04 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:22:15 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:20:58 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:19:37 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:18:22 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:17:18 | View |
| 4 | Dec 18, 2025 | 2025-12-18 17:16:59 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BRY | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 36.2x | -2.4x · sector 14.8x | Elevated |
| Forward P/E (FY25E) | 32.6x | EPS est. 0.10 | In line |
| Price / Book | 0.4x | 0.7x | Discount |
| Price / Sales | 0.8x | 0.7x | Elevated |
| EV / EBITDA | 5.5x | 1.9x | Elevated |
| Return on equity | 1.2% | — | Weak |
| Gross margin | 26.6% | 31.8% | Below hist. |
| Debt / Equity | 0.63 | 0.56 | Moderate |
| Piotroski / Altman Z | 4/9 | Z 0.47 | Distress |
Discounted cash flow model